Author: Fragoso, Yara D.; Schiavetti, Irene; Carmisciano, Luca; Ponzano, Marta; Steinberg, Judith; Treviño-Frenk, Irene; Ciampi, Ethel; Vecino, Maria Cecilia A.; Correa, Edgar P.; Carcamo, Claudia; Gomes, Sidney; Pimentel, Maria Lucia V.; Santos, Gutemberg A.C.; Vrech, Carlos; Winckler, Thereza C.A.; Sormani, Maria Pia
Title: Coronavirus disease 2019 in Latin American patients with multiple sclerosis Cord-id: djpjgm86 Document date: 2021_7_25
ID: djpjgm86
Snippet: Patients with multiple sclerosis (MS) who present coronavirus disease 2019 (COVID-19) are of particular interest to neurologists. These patients have a neuroimmune disease and receive immunomodulatory or immunosuppressive therapies in the long-term. We present here data from 73 patients with MS and a confirmed diagnosis of COVID-19 from five Latin American countries. Fifteen patients (20.5%) were hospitalized and two patients died. The use of anti-CD20 therapies was the only risk factor associat
Document: Patients with multiple sclerosis (MS) who present coronavirus disease 2019 (COVID-19) are of particular interest to neurologists. These patients have a neuroimmune disease and receive immunomodulatory or immunosuppressive therapies in the long-term. We present here data from 73 patients with MS and a confirmed diagnosis of COVID-19 from five Latin American countries. Fifteen patients (20.5%) were hospitalized and two patients died. The use of anti-CD20 therapies was the only risk factor associated to hospitalization and death. Despite the small sample size, this study highlights the awareness regarding therapeutic options for MS during the pandemic.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date